The biochemistry of chronic pain and fatigue

Journal of Chronic Fatigue Syndrome

Volumn 7, Issue 1, 2000, Pages 3-21

  McGregor, Neil R ^a   Niblett, Suzanne ^b   Dunstan, R H ^a   Butt, Henry L ^a   Roberts, Timothy K ^b   King, Katrina ^c   Bligh, Phillip Clifton ^a   Fulcher, Greg ^c   Hoskin, Leigh ^a   Klineberg, Ivan ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Department of Biological Sciences   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Chronic pain; Fatigue; Nitrogen metabolism; RNase L; Staphylococci; Tyrosine

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINO ACID; ASPARTATE AMINOTRANSFERASE; CARBOXYLIC ACID; LEUCINE; TYROSINE;

ARTICLE; BIOCHEMISTRY; CHRONIC FATIGUE SYNDROME; CHRONIC PAIN; HUMAN; INFECTION; INJURY; MYOFASCIAL PAIN; NITROGEN METABOLISM; STRESS;

EID: 0033761476     PISSN: 10573321     EISSN: None     Source Type: Journal    
DOI: 10.1300/J092v07n01_02     Document Type: Article

References (62)

1. Research diagnostic criteria. Part II
2. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee
3. Chronic fatigue syndrome: A working case definition
4. A report-chronic fatigue syndrome: Guidelines for research
5. The chronic fatigue syndrome: A comprehensive approach to its definition and study
6. Chronic fatigue, chronic fatigue syndrome, and fibromyalgia. Disability and health-care use
7. Functional status in patients with chronic fatigue syndrome, other fatiguing illnesses, and healthy individuals
8. The relationship between fibromyalgia and temporomandibular disorders: Prevalence and symptom severity
9. Chronic multisymptom illness affecting Air Force veterans of the Gulf War
10. Chronic fatigue syndrome: An update
11. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection
12. Upregulation of the 2-5A Synthetase/RNase L pathway associated with chronic fatigue syndrome
13. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome
14. Persistence of enterovirus RNA in muscle biopsy samples suggests that some cases of chronic fatigue syndrome result from a previous, inflammatory viral myopathy
15. Phylogenetic analysis of short enteroviral sequences from patients with chronic fatigue syndrome
16. Simultaneous measurement of antibodies to Epstein-Barr virus, human herpesvirus 6, herpes simplex virus types 1 and 2, and 14 enteroviruses in chronic fatigue syndrome: Is there evidence of activation of a nonspecific polyclonal immune response?
17. A comprehensive immunological analysis in chronic fatigue syndrome
18. Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome
19. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: Interrelations with cellular sources and patterns of soluble immune mediator expression
20. Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome
21. A 37Jda 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome
22. A 37KDA 2-5A binding protein as a potential biochemical marker for the chronic fatigue syndrome
23. Down regulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome
24. Interferon-induced proteins are elevated in blood samples of patients with chemically or vitally induced chronic fatigue syndrome
25. 2',5' Olgio(A) polymerase activity and inhibition of viral RNA synthesis in interferon-treated HeLa cells
26. Constitutive expression of (2'-5') oligio A synthetase confers resistance to picocornavirus infection
27. Reduced steady-state levels of vaccinia virus-specific early mRNAs in interferon-treated chick embryo fibroblasts
28. Loss of (2'-5') oligioadenylate synthetase activity by production of antisense RNA results in lack of protection by interferon from viral infections
29. Hepatitis delta virus replication in vitro is not effected by interferon-alpha or-gamma despite intact cellular responses to interferon and dsRNA
30. 2',5' Oligioadenylate synthetase in interferon-alpha and acyclovir-treated herpes simplex virus-infected cells
31. Activation of the interferon-inducible (2'-5') oligoadenylate synthetase by the Epstein-Barr virus RNA, EBER-1
32. RNase-L, soluble IL-2 receptor and IL-6 levels in patients with chronic fatigue syndrome
33. Relation between depression and circulating immune products in patients with advanced colorectal cancer
34. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome
35. Side effects of alpha interferon in chronic hepatitis C
36. Mood and cognitive side effects of interferon-alpha therapy
37. Lymphocytes delay kinetics of HSV-1 reactivation from in vitro explants of latent infected trigeminal ganglia
38. Haematological and urinary amino and organic acid excretion in a cohort of patients with defined chronic fatigue syndrome
39. Total body potassium concentration in chronic fatigue syndrome
40. Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome
41. Neurally mediated hypotension and chronic fatigue syndrome
42. Vasopressin, circulating blood volume and the chronic fatigue syndrome
43. Trauma and sepsis
44. Nitric oxide in the kidney: Synthesis, localization, and function
45. Physiological role of nitric oxide in regulation of renal function in humans
46. The effect of pain severity on metabolic homeostasis in chronic temporomandibular dysfunction type 1a (myofascial) pain patients
47. The effect of illness duration on metabolic homeostasis in chronic temporomandibular dysfunction type 1a (myofascial) pain patients
48. Intracellular protein catabolism and its control during nutrient deprivation and supply
49. The role of excitatory amino acid receptors and intracellular messengers in persistent nociception after tissue injury in rats
50. Intracellular messengers contributing to persistent nociception and hyperalgesia induced by L-glutamate and substance P in the rat formalin pain model
51. Counter-regulatory hormones and the role of cytokines in the control of amino acid metabolism
52. Temporomandibular disorders. Part I: Functional status, dentomorphological features, and sex differences in a non-patient population
53. Correspondence between subjective report of temporomandibular disorder symptoms and clinical findings
54. Assessment of pain (distribution and onset), symptoms, SCL-90-R inventory responses and the association with infectious events in patients with chronic orofacial pain
55. An association of membrane damaging toxins from coagulase-negative staphylococcus and chronic orofacial muscle pain
56. Coagulase-negative staphylococcal membrane damaging toxins are associated with pain-related metabolic changes in chronic research diagnostic criteria type 1a muscle pain patients
57. Membrane damaging toxins from coagulase-negative staphylococcus are associated with temporomandibular dysfunction (TMD) in patients with chronic fatigue syndrome
58. Search for human herpesvirus 6, human cytomegalovirus and varicella zoster virus DNA in recurrent aphthous stomatitis tissue
59. Multiplex PCR for the detection of Mycoplasma fermentans, M. hominis and M. penetrans in cell cultures and blood samples of patients with chronic fatigue syndrome
60. Ampligen and chronic fatigue syndrome
61. The 2-5A System: Modulation of viral and cellular processes through acceleration of RNA degradation
62. Neuroendocrine-immune interactions and autoimmunity